Former GW Pharmaceuticals President Joins Lexaria
Mr. Gangolli said: “The potential of Lexaria’s disruptive drug delivery technology is significant and I hope to assist Lexaria in its commercial development of DehydraTECH for multiple applications.”
- Prior to being acquired by Jazz Pharmaceuticals, GW Pharmaceuticals established a world-leading cannabinoid science platform including an innovative pipeline of early and late-stage cannabinoid product candidates.
- Gangolli brings extensive pharmaceutical experience to the role of Strategic Advisor. He oversaw FDA approval of the first and only pure cannabidiol (“CBD”) drug ever approved by the FDA, Epidiolex®, and its subsequent successful commercialization in the USA.
Lexaria has stated it will intensify its focus on the commercial execution of DehydraTECH technology portfolio during 2023.